Product dose omission issue: FDA reporting patterns
280,971 FDA FAERS reports mention Product dose omission issue. 74,272 reports have a serious outcome flag.
Medicines named as suspect
- Dupilumab: 25,079 reports
- Guselkumab: 11,343 reports
- Ustekinumab: 9,966 reports
- Lenalidomide: 9,453 reports
- Fluticasone: 8,016 reports
- Mepolizumab: 6,549 reports
- Tofacitinib: 5,691 reports
- Voxelotor: 5,121 reports
- Belimumab: 5,023 reports
- Golimumab: 4,978 reports
- Apremilast: 4,736 reports
- Secukinumab: 4,708 reports
FAERS reports describe events reported after a medicine was taken. They do not prove that the medicine caused an event, measure how often a side effect occurs, or estimate personal risk.
Source: FDA FAERS via openFDA. FAERS data through 2026-06-30. Sources, methods, and limitations.